Mochida Launches Teriparatide Biosimilar for the Treatment of Osteoporosis in Japan

Shots:

• Mochida launched “Teriparatide BS subcutaneous injection Kit 600μg MOCHIDA” as it has been listed on the NIH reimbursement price list
• The launch will improve QoL and lead to the reduction of the financial burden of patients with osteoporosis. The teriparatide biosimilar has developed in collaboration with Gedeon Richter
• Teriparatide BS Injection Kit 600μg is a novel biosimilar approved in Japan targeted for osteoporosis with a recommended dose of 20 μg SC once a day that enhances bone formation and improves bone structure. It is a disposable kit preparation with the delivery device and available for self-injection

Click here to­ read full press release/ article | Ref: Mochida | Image: Mochida